Not currently recruiting at University of California Health

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

a study on Prostate Cancer Cancer, General

Summary

Eligibility
for males ages 40 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Matthew Cooperberg, MD, MPH (ucsf)
Headshot of Matthew Cooperberg
Matthew Cooperberg

Description

Summary

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

Official Title

PATROL: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

Details

OUTLINE:

Participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years.

Keywords

Prostate Carcinoma, Prostatic Neoplasms, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment

Eligibility

You can join if…

Open to males ages 40 years and up

  • People with prostates ≥40 years of age
  • Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.

You CAN'T join if...

  • Prior diagnosis of prostate cancer
  • Medical contraindication to any of the study procedures (e.g., prostate biopsy)
  • For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)
  • Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk
  • Unable to provide written informed consent
  • Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.

Locations

  • University of California, San Francisco not yet accepting patients
    San Francisco California 94143 United States
  • City of Hope not yet accepting patients
    Duarte California 91010 United States
  • OHSU Knight Cancer Institute accepting new patients
    Portland Oregon 97239 United States
  • Fred Hutch/University of Washington Cancer Consortium accepting new patients
    Seattle Washington 98109 United States

Lead Scientist at University of California Health

  • Matthew Cooperberg, MD, MPH (ucsf)
    Both clinician and patient decisions influence the choices about the type of treatment a patient will receive for localized prostate and kidney (renal) cancer. Matthew Cooperberg, MD, MPH is conducting an ongoing research program to study national prostate cancer management trends, based on data from CaPSURE and other sources.

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
University of Washington
ID
NCT04472338
Study Type
Observational
Participants
Expecting 450 study participants
Last Updated